Antiplatelet drugs
Copyright policy )Antiplatelet drugs
Abstract.The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists. The emergence of glycoprotein IIb/IIIa antagonists as the most promising competitors for aspirin has focused attention on the possibility of delivering these drugs at an effective dose safely.
- University College Dublin Ireland
Integrins, Ticlopidine, Aspirin, Animals, Humans, Arterial Occlusive Diseases, Dipyridamole, Platelet Glycoprotein GPIIb-IIIa Complex, Platelet Aggregation Inhibitors
Integrins, Ticlopidine, Aspirin, Animals, Humans, Arterial Occlusive Diseases, Dipyridamole, Platelet Glycoprotein GPIIb-IIIa Complex, Platelet Aggregation Inhibitors
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).10 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!